Enanta price target lowered to $15 from $25 at RBC Capital

RBC Capital lowered the firm’s price target on Enanta Pharmaceuticals to $15 from $25 and keeps a Sector Perform rating on the shares. The analyst says lower rates of hospitalization from both COVID-19 may reduce the Phase III feasibility, partnerability, and out-year revenue prospects of EDP-235. In addition, lower hospitalization rates for respiratory syncytial virus may increase risk of additional enrollment delays for EDP-938, the analyst tells investors in a research note. RBC sees “in-line trading” for Enanta shares over the near-term on limited catalysts and more challenging future cash flow prospects from its portfolio.